Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Summary

This reports provides a data-driven overview of the current and future competitive landscape in Alport Syndrome therapeutics.

Synopsis

• In 2022, diagnosed prevalence of Alport syndrome will reach to 359,000 cases across the 16 countries covered in GlobalData’s epidemiology forecast.
• There are no approved marketed products for the treatment of Alport syndrome.
• R&D activity in Alport syndrome is limited, with only one product in late-stage development.
• Reata pharmaceuticals dominate clinical trial development in Alport syndrome, with the US emerging as the key countries for conducting trials in Alport syndrome.
• No deal activity observed within the Alport syndrome space during the past 24 months.
• Therapeutic options for Alport syndrome patients continue to be limited, with only one therapy reaching the market during next 18 months.

Scope

GlobalData’s Alport Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include-

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Alport Syndrome market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Alport Syndrome market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.